Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study

Atherosclerosis

7 September Sep 2020 one month ago
  • Coggi D, Bonomi A, Amato M, Frigerio B, Sansaro D, Ravani A, Veglia F, Capra N, Tremoli E, Colombo GI, Baldassarre D

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key regulators of low-density lipoprotein cholesterol plasma levels. Circulating PCSK9, which differs between genders, represents a valid pharmacological target for preventing cardiovascular (CV) events. We aimed to investigate sex-related associations between PCSK9 plasma levels and biochemical and anthropomorphic factors, and familial and personal morbidities, in a large European cohort (n = 3673) of men (47.9%) and women (52.1%).

Reference

Ferri N, Ruscica M, Coggi D, Bonomi A, Amato M, Frigerio B, Sansaro D, Ravani A, Veglia F, Capra N, Lupo MG, Macchi C, Castelnuovo S, Savonen K, Silveira A, Kurl S, Giral P, Pirro M, Strawbridge RJ, Gigante B, Smit AJ, Tremoli E, Colombo GI, Baldassarre D; IMPROVE study group. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis 2020 Jul 30;309:39-46.doi: 10.1016/j.atherosclerosis.2020.07.014.

Go to PubMed